MSH Tripeptide (Melanostatin)

Status

Cosmetic ingredient. No FDA-approved drug labeling exists. Used as a cosmetic ingredient; skin-lightening claims that go beyond appearance would place a product in the drug category, which these have not been reviewed as.

What it is

A topical peptide marketed for pigment appearance.

What published research measured

A short peptide related to melanocyte-inhibiting factor, a hypothalamic tripeptide that antagonizes alpha-melanocyte stimulating hormone signalling, formulated into cosmetic preparations on the proposition that blocking that signal reduces melanin production and lightens hyperpigmentation. The evidence is weak and largely supplier-derived: there are few independent peer-reviewed controlled studies, and none establishing meaningful clinical depigmentation against an active comparator such as hydroquinone, azelaic acid or a retinoid, all of which have far better-developed literature for the same endpoint. As with the other topical peptides, penetration of a hydrophilic short peptide through intact stratum corneum is an unresolved question rather than a demonstrated property.

Source

Not tied to a single designated source; see the published research on this molecule

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.